Clinical trial · Interventional
IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) When Compared With 3D Conformal Radiotherapy (3DCRT) for Patients With Locally Advanced Rectal Cancer, Prospective Phase II Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small bowel, would result in lower rates of acute GI toxicity compared with previously reported rates.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiotherapy | — | UNRESOLVED | — |
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
| Toxicity Due to Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3-Dimension Conformal Radiation Therapy | Radiation | — | UNRESOLVED |
| Intensive Modulated Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- IMRT
- description
- Intensive Modulated Radiation Therapy
- interventionNames
- Radiation: Intensive Modulated Radiation Therapy
- type
- ACTIVE_COMPARATOR
- label
- 3DCRT
- description
- 3-Dimension Conformal Radiation Therapy
- interventionNames
- Radiation: 3-Dimension Conformal Radiation Therapy
Primary outcomes (1)
- measure
- Number of participants with treatment-related gastrointestinal and urinary adverse events as assessed by CTCAE v5.0
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with locally advanced rectal adenocarcinoma * Performance status of 0-2 * Adequate hematologic, renal, and hepatic function Exclusion Criteria: * Prior radiotherapy to pelvis * Metastatic disease at diagnosis
References
Publications (0)
Data not yet available